← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Vaxinnate Corporation
Cranbury, NJ
$4,194,955
Total funding
6
Grants
Funding over time
peak $754.1K · FY2005–16$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$4,374,617 · 5
DOD$-179,662 · 1
By mechanism
R01$2,183,992 · 1
R43$1,481,288 · 2
N01$591,076 · 1
R21$118,261 · 1
—$-179,662 · 1
Investigators at Vaxinnate Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo$754,080
R01 · FY2015 · AI
Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo$746,690
R01 · FY2013 · AI
Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo$683,222
R01 · FY2014 · AI
Discovery of Novel TLR Ligands with Adjuvant Properties$649,771
R43 · FY2004 · AI
Innate Immune Receptors and Adjuvant Discovery$591,076
N01 · FY2008 · AI
Development of a Tetravalent Dengue Vaccine that Links Innate and Adaptive Immuni$300,000
R43 · FY2008 · AI
Development of a Tetravalent Dengue Vaccine that Links Innate and Adaptive Immuni$298,530
R43 · FY2007 · AI
Discovery of Novel TLR Ligands with Adjuvant Properties$232,987
R43 · FY2005 · AI
Development of a Recombinant Zika Virus Vaccine Based on Subunit Envelope (E) Amtigen Fused to a TLR5 Agonist (Flagellin)$118,261
R21 · FY2016 · AI
RECOMBINANT MALARIA VACCINE TARGETED VIA TOLL-LIKE RECEPTORS$-179,662
· FY2008 · Department of Defense